Friday, September 27, 2013

Sulbutiamine



Introduction
Sulbutiamine is a synthetic thiamine derivative designed to overcome thiamine’s inherently poor bioavailability. It was designed in the 70’s in Japan in response to widespread thiamine deficiency. Later studies revealed that it had a significant effect on treating asthenia, a type of centrally mediated fatigue.

Physiochemistry
Sulbutiamine is a lipid soluble analogue of thiamine which has been demonstrated to increase thiamine levels in tissue. Unfortunately, very little human pharmacokinetic data exists. Studies published from Servier, the French manufacturer of sulbutiamine, indicate that peak plasma levels of sulbutiamine...







Read more 

Wednesday, August 14, 2013

Galantamine


Galantamine is by far my favorite nootropic. Not only is it a mild acetylcholinesterase inhibitor, it also positively modulates the alpha 7 nicotinine acetylcholine receptor. The end effect is a global increase in acetylcholine levels and the facilitation of the activation of the particular type of receptor intimately involved in learning and memory.

Acetylcholinesterase (AchE)
The strength of AchE inhibition is directly proportional to the reciprocal increase in the amount of acetylcholinesterase present. In other words, the stronger you inhibit the enzyme, the more the body produces to counteract its absence. This has been quantified in studies examining this effect with galantamine in comparison to donepezil, which saw much greater AchE enzyme elevation with donepezil. This isn't surprising since donepezil is roughly 40-300 times more potent at inhibiting this enzyme [1]. In the context of Alzheimer's disease, or other forms of dementia, this fact is relatively unimportant since the user will continue to supplement with the AchE inhibitor until death. Conversely, for a healthy individual using an AchE inhibitor for a relatively shorter amount of time, this may result in fairly significant rebound once supplementation ceases. This effect would be considerably more muted when supplementing with galantamine, especially since nootropic effects can be seen with doses much smaller then what is required to inhibit AchE.


Continue Reading



References
[1] http://www.ncbi.nlm.nih.gov/pubmed/15694923

Wednesday, July 10, 2013

Driven Sports Craze Adulterated with Meth Analog





It has long been suspected that Driven Sports Craze was spiked with an unlisted stimulant, although no one could have guessed quite how sinister the stimulant would turn out to be. In light of the AX Slim Xtreme controversy, it was widely assumed that if an insidious company owner would decide to spike one of their supplements, it would probably be with a non-phenylethylamine compound along the same lines as 1,3-DMAA. The latter compound is minus the benzene ring and therefore would be less likely to fall under the umbrella of the Federal Analog Act. Due to its structural dissimilarity, a non-phenyl derivative would also generate very little attention from of the FDA for at least a few years. 

Not to be deterred by the thought of a lengthy prison sentence, the owner of Driven Sports decided to release an alpha-alkylated phenylethylamine nearly undetectable with most forms of drug testing. Not only does this compound produce low cross-reactivity while intact, but that its metabolites do not share overlap with conventional amphetamine metabolites - nor even ephedrine. The compound is called N, alpha-diethyl-phenylethylamine. It is 2 carbon atoms away from methamphetamine, and 1 ketone away from a popular bath salt. Overall, the alpha-ethyl substituent would produce less dopaminergic effects, while the N-ethyl group would marginally insulate the amine from rapid deamination. The end effect would be strong CNS effects, long lasting stimulation especially when coupled with caffeine, and with minimal addictive potential.. 

Background
In early 2012, Patrick Arnold tested Craze and found that it contained N-Benzyl-2-Phenylethylamine, in addition to another compound he could not positively identify without a reference (more on this later). When Patrick announced on various forums what he had found, he received notice from Matt Cahill's lawyers to cease public communication about Craze. 

In retrospect, Matt Cahill's over-reaction to the news about Patrick's discovery should have been a huge red flag. After all, N-Benzyl-2-PEA is 1) found in nature and 2) extremely safe from being classified according to the Federal Analog Act. Instead of quieting speculation at the true contents of Craze, the legal notices simply fueled conjecture and skepticism. More importantly, however, is that the legal threats made adamant enemies out of those who would otherwise be indifferent. 


In late 2012, supplement retailers in Australia began to receive notice from the Australian government that Craze was being restricted from import due to the presence of a "methamphetamine analog." Since the notices were not public record, the Driven Sports team easily deflected the charges as based on flawed testing procedures. 


Coincidentally, also during this time period, the Australian Sports Anti-Doping Authority (ASADA) banned a professional rugby player named Troy Errington for using an extremely unique amphetamine analog that has only rarely been referenced in the literature. Interestingly enough, Mr. Errington placed blame on DS Craze. Indeed, Australia's National Measurement Institute confirmed the presence of the compound in Craze. Similarly, the Swedish government banned the importation of Craze into Sweden based on independent laboratory reports from the Swedish National Lab for Forensic Science.

While these stories were breaking, Patrick Arnold decided to re-test his Craze sample and match it to the referenced mass spec for this particular analog. Not surprisingly, it was a perfect match.



Driven Sports explanation for the magnitude of evidence against them involved an international counterfeiting conspiracy. (The Law of Parsimony may suggest that a counterfeiter producing a more effective product using a nearly untraceable designer stimulant is the height of absurdity, it did not detract from their legion of fans). They even had lab tests to prove their innocence. Despite no chain of custody for these tests, the tide of public opinion was swinging back in favor for Driven Sports.
A counterfeit warning on the Driven Sports website
All of their excuses would come to light, however, when Ron Kramer of ThermoLife International would decide to produce a reference standard for this compound. According to Matt Cahill, the owner of Driven Sports, only they had a reference standard for N, alpha-diethyl-phenylethylamine, and therefore only they could prove or disprove its presence in Craze. (Although, one might wonder why they had a reference standard for it in the first place...). Now that Ron Kramer also had a reference standard, the truth could be explored more fully. No longer could Matt Cahill point towards an elaborate European counterfeiting scheme, since Ron Kramer would purchase his Craze samples directly from authorized dealers of Driven Sports in the United States.

In mid-June, Ron Kramer posted the first series of results from Craze testing:


Consumer Warning:  Driven Sports Craze Spiked with Designer Stimulant?

Sunday, May 5, 2013

Pharmacology of Hederagenin


Introduction 
Hederagenin is a highly water insoluble triterpenoid compound that can be found in various plants including Hedera helix and Chenopodium quinoa. It has been used as a component of the Fructus akebiae extract (FAE) in Traditional Chinese Medicine for the treatment of depression. In rodent studies, hederagenin was identified as the active compound in FAE and was determined to have potent anti-depressant qualities.

Hederagenin as a Psychotropic Drug 
In a 2010 study, Chinese researchers extracted and purified hederagenin from FAE and tested the compound on rats exposed to stress-inducing experiments [1]. As compared with the proven antidepressant escitalopram, hederagenin performed equally in reducing overt signs of stress. Additionally, hederagenin was shown to decrease biochemical markers of distress including serum ACTH and cortisol. In 2012, the same group of researchers further elucidated the mechanisms behind the antidepressant nature of hederagenin [2]. In an en vitro experiment, they found that hederagenin markedly inhibited the serotonin, norepinephrine, and dopamine, monoamine transporters with a Ki of 3.89±0.18 nm, 0.22±0.04 nm, and 2.87±0.54 nm, respectively. (As a comparison, cocaine is known to inhibit these transporters with a Ki of between 0.2 and 0.7 micromoles, which is several orders of magntitude less potent than hederagenin). To support their results, the researchers then used microdialysis to directly measure the CNS monoamine levels of living rats exposed to varying armounts of FAE. They found that FAE at doses of 12.6, 25, and 50 mg/kg significantly increased the extracellular concentrations of serotonin, norepinephrine, and dopamine, which would be expected with reuptake inhibition. Converting this to a Human Equivalent Dosage (HED) for a 70 kg adult equates to about 142 to 565 mg's.

Pharmacokinetics
In 2011, a benchmark study was conducted to examine the pharmacokinetics of orally administered hederagenin in rats [3]. They found that not only was hederagenin orally bioavailable, but that it successfully crossed the blood brain barrier (BBB). The former is surprising since similar compounds are known to have exceptionally poor bioavailability, even in rats.

Physicochemical Characteristics and Kinetic Predictions
Hederagenin is an acidic and hydrophobic compound with a pKa of 4.9 and a Log Sw of -6.92. It has an estimated volume of distribution (Vd) of 0.41 L/kg, an estimated GI transluminal diffusional capacity of 30-70%, and a blood brain barrier permeability coefficient (LogPS) of -3.5 [4].

My Interpretation
Most of the positive studies done on hederagenin were performed by the same institution (Southern Medical University, Guangzhou, China), and mostly by the same group of researchers [1, 2, 3]. And although I do not propose any research fabrication or bias, results this impressive should be replicated and verified. Similarly, although the rat pharmacokinetic study referenced above showed adequate bioavailability and BBB penetration, I suspect this will not be the case with humans.

For example:

  • With an estimated Vd of 0.41 L/kg, it is expected that this compound would be restricted to the total body water (TBW)
  • Acidic compounds without basic groups (pKa >6) are known to have limited distributive properties due to high-affinity binding to complexes I & II on serum albumin.
  • Based on albumin-dissociation calculations, only 0.0072% would be expected to be unbound in plasma [5], which would further restrict its Vd from the TBW to the vascular compartment.
  • Despite being highly hydrophobic (Log P: 7.08), which lends itself to BBB penetration, hederagenin would be heavily ionized in the plasma and therefore much less likely to cross the blood brain barrier.

Summary
Hederagenin is a very interesting compound which has demonstrated potent monoamine reuptake inhibitory properties in at least one study. These results are not exceptionally surprising since hederagenin is a component of an extract that is commonly used to treat depression in China. Unfortunately, there are no human safety or pharmacokinetic studies, and the existing en vitro and animal studies have not been independently replicated. Furthermore, the compounds chemical structure itself inspires doubt as to its true bioavailability and BBB accessibility, which I predict to be much worse. Ultimately, the studies performed on this compound to date are a great starting point but much more research is necessary to reconcile its physicochemical disparity with the remarkable effects it seems to be capable of. 


References
[1] http://www.ncbi.nlm.nih.gov/pubmed/19931301 
[2] http://www.sciencedirect.com/science/article/pii/S0091305711003236 
[3] http://www.ncbi.nlm.nih.gov/pubmed/21680262
[4] http://www.ncbi.nlm.nih.gov/pubmed/9466345
[5] http://www.pnas.org/content/82/5/1563.full.pdf

Tuesday, April 30, 2013

Is Paeonol an effective MAO inhibitor?



Paeonol is a phenolic-type compound widely used as a component in Traditional Chinese Medicine (TCM). It has been reported to have analgesic, anti-inflammatory, and sedative properties. Recently Paeonol has been introduced as a Monoamine Oxidase Inhibitor in various sports supplements.

Indeed in 2004, paeonol was compared against other plant-derived compounds for their ability to inhibit Monoamine Oxidase types A & B [1]. Paeonol was found to inhibit MAO-A with an IC50 of 54.6 micromoles. It also was found to inhibit MAO-B with an IC50 of 42.5 micromoles. On the surface, this may appear useful although important pharmacokinetic questions must be made. Specifically, does oral supplementation of paeonol reach a plasma concentration necessary to actually inhibit MAO?

A look at the literature quickly answers this question. In 2007 a study was conducted to examine the pharmacokinetic parameters of oral paenol supplementation in humans [2]. They gave 160 mg of purified paeonal to 24 healthy individuals and found that the maximum average plasma concentration reached was 217 nanograms/mL. Converting this quantity to micromoles equals a peak plasma concentration of 0.0013 micromoles, or 33,000 times lower than the concentration necessary to inhibit 50% of MAO-B. This effectively eliminates its potential as a Monoamine Oxidase Inhibitor.

Summary

  • Paeonol is a constituent of various types of TCM and has been recently released as a Monoamine Oxidase Inhibitor
  • Studies show that the concentration necessary to inhibit MAO-A and MAO-B are 54.6 micromoles and 42.5 micromoles, respectively.
  • Human pharmacokinetic studies indicate that the maximum plasma concentration reached with administration of 160 mg of purified paeonol is approximately thirty-three thousand times lower than what is necessary to inhibit Monoamine Oxidase, therby rendering its usefulness as a MAO inhibitor null.

References